← Back to patent-cliff list
CAS 131175-87-6
(1R,4S,5R,8S,9R,12R,13R)-1,5,9-Trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol(3R,5aS,6R,8aS,9R)-3,6,9-trimethyldecahydro-3H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-ol
Codes: (III)91299-1-a, Aminoarteether-002
Application context (from source-drug indications)
Plasmodium infectionArtesunate/Pyronaridine PhosphateCOVID-19Artesunate/Pyronaridine PhosphateFalciparum malariaArtesunate/Pyronaridine PhosphatePlasmodium infectionArtesunate/Mefloquine HydrochlorideFalciparum malariaArtesunate/Mefloquine HydrochloridePlasmodium infectionArtesunateIntestinal neoplasmArtesunateColon cancerArtesunateCervical intraepithelial neoplasiaArtesunateHIV infectionArtesunateCervical cancerArtesunateSystemic lupus erythematosusAminoarteether Maleate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Artesunate/Pyronaridine Phosphate | Tier C — Watch / trade | - |
| Artesunate/Mefloquine Hydrochloride | Tier C — Watch / trade | - |
| Artesunate | Tier C — Watch / trade | - |
| Aminoarteether Maleate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
Dihydroartemisinic acid→(1R,4S,5R,8S,9R,12S,13R)-1,5,9-Trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one→(1R,4S,5R,8S,9R,12R,13R)-1,5,9-Trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol→2,5-Dioxotetrahydrofuran
Dihydroartemisinic acid→(1R,4S,5R,8S,9R,12S,13R)-1,5,9-Trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one→(1R,4S,5R,8S,9R,12R,13R)-1,5,9-Trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol→2,5-Dioxotetrahydrofuran
Dihydroartemisinic acid→(1R,4S,5R,8S,9R,12S,13R)-1,5,9-Trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one→(1R,4S,5R,8S,9R,12R,13R)-1,5,9-Trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol→2,5-Dioxotetrahydrofuran
(3R,5aS,6R,8aS,9R)-3,6,9-trimethyloctahydro-3H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(12H)-one→(3R,5aS,6R,8aS,9R)-3,6,9-trimethyldecahydro-3H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-ol→(3R,5aS,6R,8aS,9R,10S)-10-(2-bromoethoxy)-3,6,9-trimethyldecahydro-3H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene→(3R,5aS,6R,8aS,9R,10S)-10-(2-azidoethoxy)-3,6,9-trimethyldecahydro-3H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene→Ethanamine, 2-[[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]oxy]-
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.